Mavorixafor (Xolremdi)

From HemOnc.org - A Hematology Oncology Wiki

Jump to navigation Jump to search

Mechanism of action

CXCR4 inhibitor

Diseases for which it is established

WHIM syndrome

History of changes in FDA indication

2024-04-30: Initial approval in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes. (Based on 4WHIM)

Also known as

Brand name: Xolremdi

Retrieved from "https://hemonc.org/w/index.php?title=Mavorixafor_(Xolremdi)&oldid=92612"